Startup Around

Startup Around

By Startup AroundBusinessTechnology
Download on the App Store

Startup Around episodes

  • Silicon Valley's most famous startup training program just scrapped its famous 'Demo Day' founder pitches and will instead make startups submit investor-friendly slides
    Microsoft in internal memo offers paid leave to employees who can't work from home while schools are closed due to the coronavirus outbreak | To read full story, visit https://startuparound.com/read/1584055806.0887477/Silicon-Valley's-most-famous-startup-training-program-just-scrapped-its-famous-'Demo-Day'-founder-pitches-and-will-instead-make-startups-submit-investor-friendly-slides?ref=audio_experience
    1 min
  • Vida Diagnostics raises $11 million to diagnose lung diseases with AI
    Vida Diagnostics, a provider of AI-powered lung imaging analysis tools, today announced that it’s raised $11 million.
    “We are driven to continuously raise the standard of care for patients with or at risk of lung disease.
    By equipping care teams with LungPrint, patient care and quality of life can be positively affected,” said Wood, who noted that lung disease impacts over 500 million people globally.
    Paige recently raised $45 million to continue its work in cancer diagnosis with AI models trained using clinical imaging data, and Aidoc nabbed $27 million for AI-assisted head, chest, abdominal, and spinal exams.
    And just last month, Qure.ai snagged $16 million for AI that spots abnormalities in chest and head scans. | To read full story, visit https://startuparound.com/read/1584054005.917525/Vida-Diagnostics-raises-$11-million-to-diagnose-lung-diseases-with-AI?ref=audio_experience
    2 min
  • Heartbeat Health raises $8.2M to improve cardiovascular care – TechCrunch
    Heartbeat Health is a startup working to improve the way that cardiovascular care is delivered, and it announced today that it has raised $8.2 million in Series A funding.
    To a large extent because that’s because the existing model works, but there’s still room to do better.
    “As of the last seven or so years, we’re in a new era where we’ve figured out how to treat people well once they get sick,” he said.
    “Ultimately, we want to be the software, the technology powering it all, but we don’t want to leave any patient behind at the beginning,” Wessler said.
    He added that the program works with most commercial insurance and is already involved in the care of 10,000 New York-area patients. | To read full story, visit https://startuparound.com/read/1584052207.6487675/Heartbeat-Health-raises-$8.2M-to-improve-cardiovascular-care-–-TechCrunch?ref=audio_experience
    1 min
  • VIDA Diagnostics Secures $11M Series C
    VIDA Diagnostics Secures $11M Series C Back to HomeCORALVILLE, IA, VIDA Diagnostics, ("VIDA"), the leader in AI-powered lung imaging analysis, today announced an $11M initial close of its Series C financing.
    The investment was led by First Analysis Corporation with initial equity participation from Blue Heron Capital and UnityPoint Health Ventures.
    VIDA can now accelerate LungPrint's market access, further connecting its benefits to the many millions of patients with lung disease."
    About UnityPoint Health VenturesFounded in 2019, UnityPoint Health Ventures makes direct investments in ideas and partners that provide an easier, more personal experience for patients and providers.
    In addition to strategic investing, UnityPoint Health Ventures provides dedicated resources to accelerate portfolio company traction within UnityPoint Health and beyond. | To read full story, visit https://startuparound.com/read/1584050415.5760539/VIDA-Diagnostics-Secures-$11M-Series-C?ref=audio_experience
    2 min
  • SBA Coronavirus Loan and other Help for Small Businesses
    This has led U.S. President Trump to order a $50 billion small business stimulus during his speech to the nation.
    SBA Coronavirus Loan and Other AssistanceThe President was urging Congress to help small businesses and deliver tax breaks.
    This SBA coronavirus loan funding should help increase financing to regions the disease has impacted most.
    And just like a major disaster, the agency will help small businesses recover from their adversity by providing low-interest loans and other assistance.
    If the President gets the $50 billion for the SBA, the money will go to help small businesses across many industries. | To read full story, visit https://startuparound.com/read/1584048611.1073678/SBA-Coronavirus-Loan-and-other-Help-for-Small-Businesses?ref=audio_experience
    1 min
  • Harbour BioMed Raises $75M in Series B+ Venture Capital Financing
    Harbour BioMed, a Cambridge, MA- Rotterdam, The Netherlands and Suzhou, China-based global, clinical stage biopharmaceutical company, closed its $75m Series B+ round of financing.
    Backers included new investors SK Holdings, Greater Bay Area Fund, Efung Capital, Zheshang Venture Capital and Zhejiang University Future Capital and JT New Century, which joined existing investors Legend Capital, AdvanTech and GIC Pvt.
    Led by Dr. Jingsong Wang, Founder, Chairman and CEO, Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.
    The company recently reported on major progress in its clinical development programs, including:Start of Phase 1 clinical studies with HBM4003 for the treatment of advanced solid tumors.
    Phase 2/3 studies for several of these indications are expected to begin in the first half of 2020 in Greater China. | To read full story, visit https://startuparound.com/read/1584046807.971962/Harbour-BioMed-Raises-$75M-in-Series-B+-Venture-Capital-Financing?ref=audio_experience
    2 min
  • UrbanLeap Raises $4.2M Seed Round
    UrbanLeap Raises $4.2M Seed Round Back to HomeSAN FRANCISCO, CA, UrbanLeap today announced $4.2 million in seed funding.
    The financing round was led by StageOne Ventures, and with participation from existing investor lool Ventures.
    UrbanLeap also announced today that Yoav Samet, managing partner at StageOne Ventures, and Yaniv Golan, general partner at lool Ventures, are joining the company's Board of Directors, effective immediately.
    This is why spending in the smart cities sector is expected to grow to $2.57 trillion by 2025.
    We developed UrbanLeap to help governments solve these complex challenges, and this new round of funding will help us further develop our solution to continue improving cities around the world." | To read full story, visit https://startuparound.com/read/1584045006.6423593/UrbanLeap-Raises-$4.2M-Seed-Round?ref=audio_experience
    1 min
  • Remesh Grabs $25M Series A2 Round
    Remesh Grabs $25M Series A2 Round Back to HomeNEW YORK, NY, Remesh today announced $25 million in Series A2 funding.
    Remesh, the software company utilizing artificial intelligence to reinvent the way organizations conduct research, today announced $25 million in Series A2 funding after three years of 2.5x year-over-year growth.
    To date, Remesh has raised over $38 million in its push to transform the market research industry.
    "Tightening constraints of time, manpower and resources are rendering traditional market research paradigms obsolete.
    To date, 2 million insights have been enabled by the Remesh platform. | To read full story, visit https://startuparound.com/read/1584043206.5982933/Remesh-Grabs-$25M-Series-A2-Round?ref=audio_experience
    1 min
  • Kymera Therapeutics Raises $102M in Series C Financing
    Kymera Therapeutics Inc., a Cambridge, Mass.-based biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, closed a $102m Series C financing.
    Led by Nello Mainolfi, PhD, co-founder, President and CEO, and Bruce Booth, DPhil, co-founder, Chairman of the Board (and partner at Atlas Venture), Kymera Therapeutics provides Pegasus™, a proprietary protein degradation platform to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases.
    The platform consists of informatics driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools.
    The company is planning to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine targeted oncology indications.
    It is also developing novel protein degrader therapies to target STAT3, an un-drugged oncogenic transcription factor as well as a driver of inflammation and fibrosis, in a range of cancers and chronic diseases. | To read full story, visit https://startuparound.com/read/1584041411.8962905/Kymera-Therapeutics-Raises-$102M-in-Series-C-Financing?ref=audio_experience
    2 min
  • Mercado Libre goes shopping, buys software startup Lagash
    Yesterday (11) the company announced it bought Argentine software development startup, Lagash.
    And that’s because with the move, over 350 of Lagash’s employees distributed among five Latin American countries will now join Mercado Libre.
    Founded in 2001, the software development startup from Buenos Aires is no spring chicken.
    During this time Mercado Libre had previously hired Lagash to develop projects on its behalf.
    Up until this acquisition, Lagash had staff working in its native Argentina as well as Mexico, Chile, Uruguay, and Colombia. | To read full story, visit https://startuparound.com/read/1584039617.216734/Mercado-Libre-goes-shopping,-buys-software-startup-Lagash?ref=audio_experience
    1 min

About Startup Around

From the publisher's feed

Hot startup news and stories summarized every 30 minutes across the globe. Tune in now!